The transaction is expected to close in the second half of the year, making Silk Road a wholly owned subsidiary of Boston Scientific, according to a June 19 press release.
Silk Road Medical is known for its transcarotid artery revascularization devices and has completed over 85,000 procedures to date.
The TCAR system is a minimally invasive procedure that treats carotid artery disease by temporarily reversing blood flow to prevent plaque fragments from reaching the brain.
Silk Road has a market capitalization of about $854.7 million and saw a 28% revenue increase from 2022 to 2023, according to the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.